Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Its marketed product ADCETRIS, or brentuximab vedotin, is approved by the United States Food and Drug Administration, or FDA, for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is commercially available in more than 60 countries around the world, including in the United States, Canada, members of the European Union and Japan. It is collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Seattle Genetics retains commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda has commercial rights in the rest of the world. In addition to ADCETRIS and SGN-CD33A, its clinical-stage pipeline includes five other antibody-drug conjugate, or ADC, programs consisting of SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and an immuno-oncology agent called SEA-CD40, which is based on our sugar-engineered antibody, or SEA, technology. It sells ADCETRIS through a limited number of pharmaceutical distributors.. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.